|
CLIC-2201 Clinical Trials
1 actively recruiting trial
Also known as: Autologous CD22 targeting CAR-T cells
Pipeline
Phase 1: 1
Top Sponsors
- British Columbia Cancer Agency1
Indications
- B-Cell Leukemia1
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)1
- High-grade B-cell Lymphoma1
- B-cell Acute Lymphoblastic Leukemia1
- B Cell Lymphoma1
Other1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.